Small Cell Urothelial Carcinoma

  • Anil Parwani
  • Colin Dinney
  • Arlene Siefker-Radtke
Chapter

Abstract

Small cell urothelial carcinoma remains virtually indistinguishable from its counterpart in the lung. Typically comprised of small, round blue cells with hyperchromatic nuclei and a high nuclear to cytoplasmic ratio, these tumors are associated with a very rapid proliferation rate and early metastases. Upstaging at surgery is quite common and is likely the reason for the poor clinical outcomes seen with initial cystectomy. Recent data from the first clinical trial in small cell urothelial cancer suggest more long-term survivors when chemotherapy is given prior to cystectomy. Chemotherapy followed by radiation may be a reasonable alternative in patients with tumors clinically confined to the bladder. However, the frequent presence of other variant histology and carcinoma in situ associated with small cell urothelial cancer may be one reason for the higher relapse rates, including local failure in the bladder, seen with bladder irradiation. Unfortunately, the prognosis in the setting of metastatic disease remains quite poor with an average life expectancy on the order of 1 year. Additional data indicate the incidence of brain metastases may be as high as 50 % in patients with stage 3 or greater tumors, suggesting a subset of patients in which one may consider prophylactic cranial irradiation. However, the numbers of patients treated with these paradigms remain low. Additional work is required to optimize the treatment for patients with this rare malignancy.

Keywords

Lymphoma Adenocarcinoma Etoposide Adriamycin Ifosfamide 

References

  1. 1.
    Sternberg CN, Swanson DA. Non-transitional cell bladder cancer. In: Raghavan D, Scher HI, Leiber SA, Lange P, editors. Principles and practice of genitourinary oncology. Philadelphia: Lippincott - Raven Publishers; 1997. p. 322–3.Google Scholar
  2. 2.
    Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005;103(6):1172–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 2004;101(5):957–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004;172(2):481–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009;27(16):2592–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Walther PJ. Adjuvant/neo-adjuvant etoposide/cisplatin and cystectomy for management of invasive small cell carcinoma of the bladder. J Urol. 2002;167(4):285.Google Scholar
  7. 7.
    Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, et al. Radical cystectomy for ­primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol. 2005;174(1):93–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology. 2005;46(1):57–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Blomjous CE, Vos W, De Voogt HJ, Van der Valk P, Meijer CJ. Department of Pathology FUHATN. Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer. 1989;64(6):1347–57.PubMedCrossRefGoogle Scholar
  10. 10.
    Sved P, Gomez P, Manoharan M, Civantos F, Soloway MS. Small cell carcinoma of the bladder. BJU Int. 2004;94(1):12–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Grignon DJ, Ro JY, Ayala AG, Shum DT, Ordâoänez NG, Logothetis CJ, et al. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. Cancer. 1992;69(2):527–36.PubMedCrossRefGoogle Scholar
  12. 12.
    Christopher ME, Seftel AD, Sorenson K, Resnick MI. Small cell carcinoma of the genitourinary tract: an immunohistochemical, electron microscopic and clinicopathological study. J Urol. 1991;146(2):382–8.PubMedGoogle Scholar
  13. 13.
    Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol. 2005;166(5):1533–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Tamas EF, Stephenson AJ, Campbell SC, Montague DK, Trusty DC, Hansel DE. Histopathologic features and clinical outcomes in 71 cases of bladder diverticula. Arch Pathol Lab Med. 2009;133(5):791–6.PubMedGoogle Scholar
  15. 15.
    Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009;22 Suppl 2:S96–118.PubMedCrossRefGoogle Scholar
  16. 16.
    Pant-Purohit M, Lopez-Beltran A, Montironi R, MacLennan GT, Cheng L. Small cell carcinoma of the urinary bladder. Histol Histopathol. 2010;25(2):217–21.PubMedGoogle Scholar
  17. 17.
    Ismaili N, Arifi S, Flechon A, El Mesbahi O, Blay JY, Droz JP, et al. Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. Bull Cancer. 2009;96(6):E30–44.PubMedGoogle Scholar
  18. 18.
    Buza N, Cohen PJ, Pei H, Parkash V. Inverse p16 and p63 expression in small cell carcinoma and high-grade urothelial cell carcinoma of the urinary bladder. Int J Surg Pathol. 2010;18(2):94–102.PubMedCrossRefGoogle Scholar
  19. 19.
    Abbas F, Civantos F, Benedetto P. Small cell carcinoma of the bladder and prostate. Urology. 1995;46(5):617–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Bastâus R, Caballero JM, Gonzâalez G, Borrat P, Casalots J, Gomez de Segura G. Small cell carcinoma of the urinary bladder treated with chemotherapy and radiotherapy: results in five cases. Eur Urol. 1999;35(4):323–6.CrossRefGoogle Scholar
  21. 21.
    Bex A, de Vries R, Pos F, Kerst M, Horenblas S. Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. World J Urol. 2009;27(1):101–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Asmis TR, Reaume MN, Dahrouge S, Malone S. Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at the Ottawa Hospital Regional Cancer Center. BJU Int. 2006;97(4):711–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Lohrisch C, Murray N, Pickles T, Sullivan L, British Columbia Cancer Agency VBCC. Small cell ­carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer. 1999;86(11):2346–52.PubMedCrossRefGoogle Scholar
  24. 24.
    Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20(14):3072–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Anil Parwani
    • 1
  • Colin Dinney
    • 2
  • Arlene Siefker-Radtke
    • 3
  1. 1.University of Pittsburgh Medical Center ShadysidePittsburghUSA
  2. 2.Department of UrologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Department of Genitourinary Medical OncologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations